Document is current

Article History

Received: 5 December 2023

Accepted: 26 February 2024

First Online: 21 March 2024

Declarations

:

: These studies will be conducted in accordance with the protocol and with the following:UnorderedList removed

: Not applicable.

: The authors wrote the article with the assistance of a medical writer funded by the sponsor. The sponsor was involved in the study design and the writing of the report.FS discloses consultant fees for Amgen, Bayer, GSK, Otsuka, and Roche, and advisory committee fees for Alnylam and Bayer. GM discloses advisory committee fees for Alynlam, Bayer, and Chiesi Farmaceutici. JVW discloses advisory committee and consultant fees from Bayer. MFS discloses consultant fees from Bayer and Travere Therapeutics. ML has nothing to disclose. JZ discloses speaker honoraria (including speakers’ bureau, symposia, and expert witness) for Alnylam, Horizon, and Natera, and advisory board fees for Bayer and Kaneka. AS, HS, JAP, PI, and SB are Bayer employees. BAW discloses consultant fees from Amgen, Roche, and GSK.